SS-31 (Elamipretide).
Mitochondrial-targeted tetrapeptide — preserves cardiolipin under oxidative stress.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About SS-31 (Elamipretide).
SS-31 (Elamipretide) is a synthetic tetrapeptide engineered to selectively concentrate in the inner mitochondrial membrane, where it binds cardiolipin and protects mitochondrial cristae structure under oxidative stress.
Phase 3 trials have explored Elamipretide in Barth syndrome and mitochondrial myopathies. Magistral use covers a broader spectrum of mitochondrial-stress contexts under physician supervision.
SS-31 binds cardiolipin in the inner mitochondrial membrane, stabilising cristae architecture and protecting the electron-transport chain. This preserves ATP production, reduces mitochondrial reactive-oxygen-species generation and prevents the release of pro-apoptotic factors.
Subcutaneous injection, typically 40 mg once daily. Cycles vary by indication.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- 01Reid Thompson W, et al. — Elamipretide in Barth syndrome: TAZPOWER results. Genet Med · 2020 · doi: 10.1038/s41436-020-00966-5
- INN / Name
- SS-31 (Elamipretide)
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 5mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.
Within Healing & Recovery.
- Cat. 01
BPC-157
Synthetic pentadecapeptide derived from human gastric juice — broad tissue-repair signalling.
€60.00 - Cat. 01
TB-500 (Thymosin Beta)
Synthetic version of Thymosin β-4 — actin regulation, angiogenesis and cell migration in injured tissue.
€60.00 - Cat. 01
KPV
α-MSH C-terminal tripeptide with strong anti-inflammatory action.
€30.00